Lucy Haslam has been a leading advocate for patient access to medical cannabis since witnessing the relief her son Dan had from using cannabis when he was terminally ill. Lucy has been at the forefront of a movement to make medical cannabis more accessible in Australia.
This conversation follows from earlier episodes explaining what is medical cannabis, what are the regulatory frameworks in Australia, the market forces impacting a lack of investment in clinical trials which limits the number of registered cannabis products, and developments in cannabinoid science. You may wish to listen to these first to contextualise this most recent discussion.
More about developments in cannabinoid science following a previous discussion about medical cannabis. Professor of Psychopharmacology Iain McGregor is Academic Director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Iain explains the human endocannabinoid system and potential medical uses of various components of cannabis, and comments on Australia’s regulatory approach to medical cannabis.
A discussion of medical cannabis and the regulatory frameworks and market forces which impact its availability in Australia and elsewhere. Nick Lintzeris is a director of drug and alcohol services in Sydney, a conjoint professor with the Faculty of Medicine at the University of Sydney, and a chief investigator for the newly established Australian Centre for Cannabinoid and Clinical Research Excellence.